NEWS
Artelo Biosciences Announces Promising New Data on Novel Non-Opioid Treatment Approach for Osteoarthritis Pain at the 13th Annual Musculoskeletal Repair and Regeneration Symposium
SOLANA BEACH, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological conditions, announced new data being presented today on ART26.12, Artelo's lead clinical Fatty Acid Binding Protein 5 (FABP5) inhibitor, in osteoarthritis (OA) pain at the 13th Annual Musculoskeletal Repair and Regeneration Symposium in New York. This evidence adds OA pain to the list of pain types such as neuropathic and cancer bone pain where ART26.12 has shown potential as an analgesic with a novel mechanism of action.
In this new research conducted at Stony Brook University, ART26.12 demonstrated more responsive symptom relief in a surgical rodent OA model than naproxen, a commonly used nonsteroidal anti-inflammatory drug (NSAID) in the treatment of OA. ART26.12 significantly improved weight-bearing on affected limbs at all three doses studied, indicating a reduction in OA-induced pain. Importantly, ART26.12 demonstrated a clear dose-response relationship, with higher concentrations yielding greater pain relief and more rapid responses than naproxen.
The study, entitled "Fatty Acid Binding Protein 5 Inhibitor, ART26.12, is a Novel Analgesic for Osteoarthritis Pain," was conducted by the Department of Orthopedics and Rehabilitation and the Department of Anesthesiology at the Renaissance School of Medicine at Stony Brook University by Drs. Kai Bou, Adam Bruzzese, Kaitlin Farrell, Chris Gordon, David Komatsu and Martin Kaczocha. "We are encouraged by these behavioral data showing efficacy for ART26.12 in alleviating osteoarthritis pain," said Dr. Komatsu of Stony Brook University. "Furthermore, we are dedicated to completing our remaining analyses to gain a comprehensive understanding of the biological response to this promising compound."
In this new research conducted at Stony Brook University, ART26.12 demonstrated more responsive symptom relief in a surgical rodent OA model than naproxen, a commonly used nonsteroidal anti-inflammatory drug (NSAID) in the treatment of OA. ART26.12 significantly improved weight-bearing on affected limbs at all three doses studied, indicating a reduction in OA-induced pain. Importantly, ART26.12 demonstrated a clear dose-response relationship, with higher concentrations yielding greater pain relief and more rapid responses than naproxen.
The study, entitled "Fatty Acid Binding Protein 5 Inhibitor, ART26.12, is a Novel Analgesic for Osteoarthritis Pain," was conducted by the Department of Orthopedics and Rehabilitation and the Department of Anesthesiology at the Renaissance School of Medicine at Stony Brook University by Drs. Kai Bou, Adam Bruzzese, Kaitlin Farrell, Chris Gordon, David Komatsu and Martin Kaczocha. "We are encouraged by these behavioral data showing efficacy for ART26.12 in alleviating osteoarthritis pain," said Dr. Komatsu of Stony Brook University. "Furthermore, we are dedicated to completing our remaining analyses to gain a comprehensive understanding of the biological response to this promising compound."
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2479Followers
107Following
27KVisitors
Follow